Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Hong Sun

DPhil Student in Clinical Medicine

HIV-1 specific HLA-E-restricted CD8 T cells

Despite considerable success of effective therapeutic regimens, HIV infection is still a life-threatening disease that cannot be curable and preventable. Therefore, an efficient prophylactic vaccine is urgently needed. HLA-E is a non-classical MHC-Ib molecule that is characterized by ubiquitously low-level expression on the cell surface and highly conserved among humans, and the role of HLA-E was originally identified in immune tolerance. Recent studies in monkeys have demonstrated that a rhesus cytomegalovirus (RhCMV) vectored simian immunodeficiency virus (SIV) vaccine protects more than 50 percent of monkeys upon highly pathogenic SIV challenge, providing the prior evidence of HIV specific CD8 T cell immune responses against MHC-E-restricted HIV/SIV peptides. The protection far better than any previous vaccines and is uniquely mediated by CD8 T cells that see SIV peptides presented by the monkey equivalent of HLA-E, called Mamu-E. The work is to delve into the existence of human CD8 T cells specific for HIV peptides bound to HLA-E and their preferentially functional profile, and then to examine the factors influencing HLA-E restricted antigen presentation process.